CTRI/2021/04/033055已完成未知
Cognitive Function in Schizophrenia in Remission, Their Healthy Siblings and Healthy control: A Comparative Study
isha Devi0 个研究点目标入组 75 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Diagnosed case of schizophrenia based on ICD-10 Criteria & duration of illness 2-5yrs.
- •2.Either Sex Aged between of 18-50yr.
- •3.Educated till 5th standard and had adequate hearing and visual abilities.
- •4.Healthy participants to be assess on the basis of General Health Questinnaire-12 items where participants scoring below 3 will be considered as healthy participants.
- •5.Remitted patient of schizophrenia
- •6.The control group and siblings of patient of schizophrenia should be matched on the basis of age group, education and socio-demographic profile.
排除标准
- •1.Clinically diagnosed mental retardation, and other mental illness which interfere the cognition in study group.
- •2.Those with history of receiving ECT in last 6 month.
- •3.History of neurological disorders (i.e. epilepsy, delirium). Other medical cause of cognitive impairment.
- •4.Those who have not given inform consent.
研究者
相似试验
尚未招募
Unknown
Cognitive training for patients with schizophrenia in forensic psychiatry: a pilot studyF20SchizophreniaDRKS00034230VR-Klinikum Düsseldorf15
招募中
不适用
Cognitive training for schizophrenia: a randomized controlled trialSchizophreniaJPRN-UMIN000039521Shinshu University86
招募中
不适用
Psychiatric and cognitive function in patients with Neuroendocrine tumours with carcinoid syndrome.cognitieve stoornissencognitive impairment10027946depressionNL-OMON45631ederlands Kanker Instituut85
进行中（未招募）
1 期
Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus TolcaponTOCTAP (Treatment of Cognitive Deficits in Schizophrenia with Tolcapone and Pergolide) - TOCTAPDas vorliegende Projektvorhaben dient der Untersuchung, inwieweit bei Patienten mit schizophrenen Störungen neben einer bestehenden Monotherapie mit Paliperidon (Invega), dem zuletzt zugelassenen neuartigen Antipsychotikum der sog. zweiten Generation, eine additive prodopaminerge Psychopharmakotherapie mit Tolcapon (Tasmar) oder Pergolid (Parkotil) die präfrontalen kognitiven Funktionen beeinflusst.EUCTR2008-006905-18-DERWTH Aachen University60
已完成
不适用
Treatment Of Cognitive deficits in schizophrenia with Tolcapone And PergolideSchizophreniaISRCTN42412532RWTH Aachen University (Germany)60